What is Amneal Pharmaceuticals, Inc.'s specialty — R&D?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — R&D of $5.1M in Q1 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — R&D changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — R&D decreased by 43.7% year-over-year, from $9.06M to $5.1M.

What does specialty — R&D mean?

Expenditures dedicated to the discovery, clinical development, and regulatory approval of new specialty pharmaceutical products. This investment is critical for long-term pipeline growth and sustaining the competitive advantage of the specialty portfolio.

Amneal Pharmaceuticals, Inc. AMRX Specialty — R&D

Other segment segments

Affordable Medicines

$28.01M-42.4%

AvKARE

$0—

Similar metrics at other companies

ESISpecialties — R&D

$3.5M+6.1%

CHDSpecialty Products Division — Research And Development Expense

$800K+33.3%

TMOSpecialty Diagnostics — Research and development expenses

$44M-2.2%

UTHRR&D

$138.2M-7.2%

ABTEstablished Pharmaceuticals — R&D

$41M-2.4%

WSTProprietary Products — R&D

$15.8M-3.1%

Other financials

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s specialty — R&D?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — R&D of $5.1M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — R&D changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — R&D decreased by 43.7% year-over-year, from $9.06M to $5.1M.
What does specialty — R&D mean?: Expenditures dedicated to the discovery, clinical development, and regulatory approval of new specialty pharmaceutical products. This investment is critical for long-term pipeline growth and sustaining the competitive advantage of the specialty portfolio.